Accera to sponsor National Memory Screening Day of Alzheimer's Foundation of America

Accera has developed and sells Axona^®, a specially formulated, prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate AD.  It is the first proprietary commercialized AD therapy that addresses the well-recognized physiological hallmark of the brain's inability to optimally metabolize glucose (hypometabolism) by providing an alternative energy source for brain cells.

Eric J. Hall, AFA's president and CEO, stated, "The Alzheimer's Foundation of America is delighted to have the continued support of Accera as a sponsor of National Memory Screening Day.  Its support underscores the company's recognition of the importance of proper diagnosis and its desire to help us fulfill our mission of improving quality of life for people with Alzheimer's disease and their families."  NMSD, an annual initiative initiated by AFA in 2003, provides free, confidential memory screenings to individuals concerned about memory loss or who want to check their memory now and for future comparison with the objective of early detection and intervention.  Qualified healthcare professionals offer the face-to-face screenings and distribute educational materials about memory concerns and successful aging in communities across the nation.  The screening results do not represent a diagnosis, but can indicate whether someone with below-normal results or with concerns should follow up with a physician.